CommuniTreat

A New Era in Wildlife Management

A humane, non-surgical oral fertility platform for mammals — a scalable, non-lethal alternative to culling for the overpopulated and invasive species reshaping our ecosystems. Proof-of-concept established in cats and rodents.

Mammal-wide
One oral platform, designed for a reproductive pathway conserved across mammals
100%
Of treated animals showed the target effect — in both cats and rodents
~$1
Per animal, per day — our field-study cost basis
Early-stage proof-of-concept. A one-year field study is now underway.
The problem

The most damaging invasive and overpopulated species on Earth are mammals

From feral cats and rodents to wild boar, deer, and coyotes, overpopulated and invasive mammals are among the most destructive forces facing ecosystems, economies, and communities worldwide — collapsing native biodiversity, spreading disease, and damaging crops and infrastructure. The control programs meant to help — culling, poisoning, trapping — never solve the problem at its source: reproduction.

Ecological
2.4B + 12.3B
birds & mammals killed each year in the US by free-ranging cats
Loss, Will & Marra, 2013 — Nature Communications
Management burden
$7–16B
modeled annual cost of managing free-roaming cats in the US
John Dunham & Associates, 2010
Rodent damage
~$19B/yr
damage from invasive rodents each year in the US
Pimentel et al.

And these are only examples. Multiply them across wild boar, deer, and other overpopulated mammals on every continent, and the true ecological, economic, and humane cost is far greater. The world needs a humane way to manage reproduction — at scale, across species.

Global economic impact

the cost of getting this wrong runs to the hundreds of billions

Invasive and overpopulated species aren't only an ecological problem — they are one of the largest and fastest-growing economic burdens on Earth.

$423B+ / yr
the global cost of invasive species — and it has quadrupled every decade since 1970.IPBES, 2023 — a conservative minimum
$462B
global cost of invasive mammals (1960–2021)
RabbitCatBlack ratWild boarCoypu
The five costliest invasive mammals — cats, rats and wild boar are all core CommuniTreat targets.
Wang et al., 2023
$1.29T
total reported cost of biological invasions since 1970
Diagne et al., Nature, 2021
$2.5B / yr
US feral-swine damage & control, every single year
USDA APHIS

Figures are conservative minimums; global costs standardized to 2017 US$ (InvaCost methodology). Reported costs consistently understate the true total.

Why today's tools fail

Two options. Both fall short.

Poison & lethal control

Effective on paper — and unacceptable in practice: inhumane, ecologically damaging (secondary poisoning up the food chain), and rejected by the communities who live with these animals.

Trap-neuter-return & surgery

Humane, but it doesn't scale: every animal means a trap, an anesthetic, a surgeon, and a recovery — slow, costly, and impossible to sustain across species and continents.

The world has been forced to choose between what's humane and what's scalable. CommuniTreat is built to end that trade-off.

The solution

One platform, many species

CommuniTreat is a non-surgical, orally delivered fertility technology built on dual plant-derived botanical actives — eaten by choice in ordinary food, acting on a reproductive pathway conserved across mammals. Not a single product for a single animal: a delivery-and-mechanism platform, engineered for breadth, with proof-of-concept demonstrated in cats and rodents.

01

Gonad-selective

Concentrates its effect on reproductive tissue, sparing surrounding organs — shown in both cats and rodents.

02

Non-hormonal

Plant-derived botanical actives rather than synthetic hormones — a gentler route to fertility control.

03

Behavior preserved

Designed to leave natural behavior intact, so treated animals keep their place in the ecosystem.

04

Safe by design

Developed with safety as a first principle. No clinical signs of toxicity and zero mortality were observed across the feline study.

05

Voluntary

Eaten by choice from feed — no trapping, no handling, no stress to the animal or the caregiver.

✓ Proof-of-concept today
Community catsRodents

Two very different mammals, one consistent result. That cross-species reproducibility is our strongest evidence that the approach generalizes.

Designed to extend to
Wild boar / feral pigsDeerOther invasive mammals

The same platform is designed to extend to other overpopulated mammals as a humane alternative to culling — each a validation step ahead of us, built on a mechanism we've already demonstrated twice.

The proof

Early evidence, honestly reported

A controlled feline proof-of-concept and the rodent studies that came before it point the same direction — a high effect rate, selective action, delivered through the animal's normal diet.

Gonadal pathology score — control vs treated (cats, males)

0.30
Control
2.83
Treated
Composite severity, scale 0 (normal) → 4 (maximal) · 20-week study, 22 analyzable cats
Welch t-test, p = 0.041 · 100% of treated cats responded
Feline proof-of-concept

Conducted with the Hebrew University of Jerusalem's veterinary teaching hospital and study lead Dr. Smadar Tal: 26 cats enrolled, 22 analyzable, over a 20-week feeding period — the actives delivered in ordinary twice-daily food.

  • 100% of treated cats — male and female — showed the targeted reproductive-tissue changes.
  • Tissue-selective: the uterus was spared in 8 of 9 females examined.
  • Zero mortality across 20 weeks.
No clinical signs of toxicity and zero mortality were observed across the study.

Early-stage proof-of-concept, not outcomes from a marketed product.

the mechanism, validated first in rodents

Before the feline work, CommuniTreat established the biological foundation of the platform in rodents. In a repeated-dose study, 100% of treated males showed the targeted testicular changes while the accessory reproductive glands remained normal — the same tissue-selective signature later reproduced in cats. Two species, one consistent result: evidence we're acting on a conserved biological pathway, not a single-species quirk.

What's next

Real-world validation in Hawaii

Laboratory proof is the beginning. The next milestone is showing the platform works in the field, at colony scale, in the messy conditions of the real world.

CommuniTreat has an approved field study on the Big Island of Hawaii — a community cat colony run over about a year, with the actives delivered simply by drizzling a palatable syrup onto the colony's normal food.

It's designed to demonstrate what a controlled study can't: real-world uptake, at-scale delivery, and population-level fertility control in an open colony — validated with established field-operations and colony-data partners on the ground. Hawaii is the ideal proving ground: its native wildlife is under acute pressure from free-roaming cats, and its communities are actively seeking humane, non-lethal alternatives.

~30
cat community colony, Big Island
~1 yr
real-world study duration
~$1/day
per cat — built for scale
Approved
greenlit with state biologists
Market

A large market, entered through the right door

We start where the need — and the data — are clearest, inside a market measured in the tens of billions.

TAM — total market
$62.9B → $112.3B
Global animal-health market by 2030 (10.5% CAGR). Source: Grand View Research.
Beachhead — where we start
$24.5B
Feline population-management opportunity. CommuniTreat internal estimate.
Expansion — where we grow
~$5.9B
Global rodenticide market (2024) — our next adjacent category.

One proven platform, three widening rings of demand — a focused feline beachhead, expanding into rodent control, and growing into the full animal-health market.

Collaborations

Building it in the real world, with the right partners

We're collaborating with field and data partners to move from proof-of-concept to real-world evidence.

Aloha Animal Alliance
Field study · Hawaii
Meow Metrics · Zoometrics
Data engine
Israel Innovation Authority
Grant support
Hebrew University
Veterinary teaching hospital
Let the Animals Live
NGO partner
Vet-Holim
Veterinary hospital

Collaborations reflect active, non-binding working relationships.

Regulatory & pipeline

A faster path, taken responsibly

Because the technology is delivered through feed, we are pursuing a feed-supplement route — a faster, more accessible path than a full pharmaceutical filing, without cutting corners on evidence.

Phase 1

Rodents

First market entry via the feed-supplement path — the fastest regulatory route.

Phase 2

Community cats

Our lead beachhead — backed by the proof-of-concept and the field study now underway.

Phase 3

Wildlife & invasive mammals

The long-horizon opportunity: humane population management across broader ecosystems.

Team

Led by veterinarians, scientists, and operators who've built before

A team that pairs deep veterinary and reproductive science with the discipline to bring it to market.

Dr. Itay Srugo
Dr. Itay Srugo
Chief Executive Officer
Dr. Tami Ehrmann-Barr
Dr. Tami Ehrmann-Barr
Scientific Director
Dr. Hilik Marom
Dr. Hilik Marom
Clinical Director
Dr. Hagit Beyar-Goldberg
Dr. Hagit Beyar-Goldberg
VP R&D
Amir Chacham
Amir Chacham
Chief Financial Officer
Dr. Smadar Tal
Dr. Smadar Tal
Veterinary / Study Lead

Protected across major markets

Patent-pending across Europe, the US, China, India, Australia, Canada, and Israel.

  • Proprietary composition — patent-pending, 2021 priority date.
  • Broad multi-market coverage — seven jurisdictions filed.
  • Clean freedom-to-operate.
Get involved

Join the New Era

Whether you want to run a study with us, back the science, or bring it to a new market — there's a place for you in what comes next. Tell us where you fit, and we'll be in touch.